IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat disease

Contributed by: Business Wire

Logo

Tags

Technology

Biotechnology

Health

Finance

Professional Services

Artificial Intelligence

Other Science

Research

Infectious Diseases

General Health

Health Technology

Science

Data Management

Clinical Trials

biotechnology

More Like This

IMU Biosciences Adopts Curiox's Pluto for Large-Scale UK Immune Profiling Initiative

IQM Quantum Computers Raises over $300 Million in Series B Funding Round Led by U.S. Investor Ten Eleven Ventures With Strong Support From Tesi

Surge announces closing of a €7.5 million fundraising round to decrypt the immune system and transform precision medicine

Nearly £50 million unlocked for world-leading UK Biobank following new industry backing

Bioptimus Hits $76M Funding Milestone and Prepares to Launch Groundbreaking Foundation Model for Biology

Endometrial immune Profiling and Precision Care Lead to Significantly Higher Live Birth Rates, MatriceLab Trial Shows

PR Newswire associated0

Ability Biologics Announces the Closing of its US $18 Million Seed Funding Extension toward the Generation of Novel, Highly Targeted Immunomodulators

MiLaboratories co-founders: Dmitry Chudakov, Stan Poslavsky, Dmitry Bolotin, Alexey Nechaev (Photo: Business Wire)

MiLaboratories Secures Series A, Raising Total Funding to $10 Million to Revolutionize the World of Genomic Research